Prior studies showed that type I PRMT and type II PRMT5 inhibitors are effective specifically in MTAP-deficient cells (43, 53); yet, our data in MTAP-intact cancer cells show that targeting PRMT1 reduces persistence (Figs. 2C, 3B, and E; Supplementary Fig. S2A). Here, PRMT1 is linked to cancer.